Menu

Top Stories

Published on Thursday, July 11, 2019

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Almost two years have passed since Nicole and Josef Ward’s son, Jude, had a liver transplant due to Alpha-1 Antitrypsin Deficiency (Alpha-1). You can read that story by clicking here.

Most people diagnosed with Alpha-1 don’t exhibit symptoms until they reach adulthood, when underproduction of the alpha-1 antitrypsin protein leads to complications in the lungs and eventual lung disease, according to the Children’s Organ Transplant Association (COTA). However, Jude was producing an abnormal form of the protein, which started pooling in his liver, damaging it.

By 22 months of age, Jude was experiencing serious liver problems. In December 2016, he was rushed to an emergency room, where doctors said Jude would need a life-saving liver transplant to survive.

The family quickly got Jude onto the waiting list for a liver transplant at a hospital in their native Florida, did seemingly endless research on liver disorders in children, and eventually joined COTA.

The Wards, who now live on the joint base, ended up having better luck seeking a transplant at the Children’s Hospital of Philadelphia.

“On July 6, 2017, at 7 am, we got our first call that the hospital had a possible liver match for Jude,” Nicole Ward recalled. “We spent the entire day at the hospital doing pre-op tests on Jude and making him fast only to find out at 9:30 pm that upon retrieval of the liver it was determined not to be the best match for our Jude. We went back to our temporary transplant home broken more than ever but still clinging to a little hope that Jude’s call would come soon,” she added.

A couple of weeks later, Jude was back in the hospital for complications of his liver disease. By July 19, doctors had found a match for him, and the next day, he had a successful surgery.

“We were very relieved but could not quite let ourselves believe this was the one until he was wheeled into surgery about midnight that same night,” Ward said.

In the months leading up to the surgery, the Wards said Jude’s body was failing him. He could only take in food through a feeding tube, he needed infusions to get rid of excess fluid in his stomach, he was tired all the time but could not sleep comfortably, and he would get bruises and sores that didn’t heal.

Though Jude, now 4, had a successful transplant, it still impacts his life in small ways, as he must make frequent visits to the transplant center for lab work, checkups and adjustments to his immunosuppression medications, his family said.

While the family temporarily lived in Philadelphia at the Gift of Life Family House, COTA was able to raise more than $60,000 for COTA in honor of Jude and his medical expenses.

The family also fears they might go through a similar journey all over again. Their daughter Lucie, born last July, has the same deficiency. She is now in the process of receiving regular lab work to check her liver enzymes and regular ultrasounds.

“We do not know where things are headed with Lucie and a liver transplant, but her doctors are keeping a close eye on her,” Ward said.

“Life after transplant is a balance of enjoying life but also being mindful of keeping Jude healthy. The biggest blessing our family has received is the blessing of perspective,” she finished.

Sources: Burlington County Times, Children’s Organ Transplant Association

Photo courtesy of the Children’s Organ Transplant Association.


Print

DNA data shared in ways patients may find surprising

Tuesday, August 13, 2019
Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to...
Divider

Arrowhead Pharmaceuticals doses first patient in SEQUOIA Phase 2/3 Study of ARO-AAT for treatment of Alpha-1 liver disease

Thursday, August 8, 2019
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference...
Divider

CSL Behring announcement on their product Zemaira

Tuesday, August 6, 2019
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “CSL Behring...
Divider

The 28th Annual Alpha-1 National Conference: The Alpha of Tomorrow

Tuesday, July 23, 2019
Orlando, Florida was the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community in the world, as the Alpha-1 Foundation held its 28th Annual Alpha-1 National...
Divider

Save the date: Developing Therapeutics for Alpha-1 Antitrypsin Deficiency Workshop

Friday, July 19, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled "Developing Therapeutics for Alpha-1 Antitrypsin Deficiency." The federal agencies will distribute a formal...
Divider

Alpha-1 Foundation earns highest not-for-profit accreditations

Monday, July 15, 2019
The Alpha-1 Foundation earned the 2019 Platinum Seal of Transparency, the highest level of recognition offered by GuideStar, the world’s largest database and source of nonprofit information, and received a 4-star rating from Charity...
Divider

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Thursday, July 11, 2019
Almost two years have passed since Nicole and Josef Ward’s son, Jude, had a liver transplant due to Alpha-1 Antitrypsin Deficiency (Alpha-1). You can read that story by clicking here. Most people diagnosed with Alpha-1 don’t exhibit...
Divider

Dicerna to begin clinical development of DCR-A1AT for treatment of patients with Alpha-1-associated liver disease

Monday, July 8, 2019
Dicerna Pharmaceuticals, Inc. announced it submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from the...
Divider

FDA grants fast track to Alpha-1-related liver disease drug

Friday, June 28, 2019
Arrowhead Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ARO-AAT, the company’s second-generation subcutaneously administered RNA interference (RNAi) therapeutic being...
Divider

Watch the 28th Annual Alpha-1 National Conference from home

Tuesday, June 18, 2019
The Annual Alpha-1 National Conference is the largest annual gathering of Alphas, their families, leading healthcare professionals, including researchers, physicians, scientists, respiratory therapists, nurse practitioners, and industry...
Divider

The Annual Alpha-1 National Conference: The largest gathering of Alphas

Tuesday, June 18, 2019
The city of Orlando, Florida, will be the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community at large, as the Alpha-1 Foundation holds its 28th Annual Alpha-1...
Divider

CSL Behring initiates voluntary recall for 4 lots of Zemaira

Thursday, June 6, 2019
The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive